Triple
T18644845
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novo Nordisk |
E455777
|
entity |
| Predicate | majorProduct |
P7216
|
FINISHED |
| Object |
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
|
E1335213
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Rybelsus | Statement: [Novo Nordisk, majorProduct, Rybelsus]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Rybelsus Context triple: [Novo Nordisk, majorProduct, Rybelsus]
-
A.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
B.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
C.
Januvia
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
-
D.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
E.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Rybelsus Triple: [Novo Nordisk, majorProduct, Rybelsus]
Generated description
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Rybelsus Target entity description: Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
A.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
B.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
C.
Januvia
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
-
D.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
E.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8d38ea1e88190997e9b231190ba6f |
completed | April 10, 2026, 10:40 a.m. |
| NER | Named-entity recognition | batch_69e5500c36188190bfdd7aca73f3c006 |
completed | April 19, 2026, 9:58 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a050d865fc48190a11ed96ebfdca50d |
completed | May 13, 2026, 11:47 p.m. |
| NEDg | Description generation | batch_6a051058f5788190b782a39feb7f6111 |
completed | May 13, 2026, 11:59 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0510fc0d1081908970c91357bb3444 |
completed | May 14, 2026, 12:02 a.m. |
Created at: April 10, 2026, 11:47 a.m.